Latest Hospitality News

EVT Limited expects normalised EBITDA growth for FY26, buoyed by hotel acquisitions and upgrades even as geopolitical tensions and site disruptions weigh on performance.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Starpharma has secured FDA alignment on the clinical development plan for its DEP® HER2 radiotherapy candidate, paving the way for a first-in-human phase 1 study in advanced HER2-positive cancers scheduled for H2 2026.

MA Financial Group reported a 44% year-on-year jump in assets under management to $14.8 billion in 1Q26, underpinned by strong lending growth and transactional activity despite asset sales and market volatility.

Ramsay Health Care has announced a fully franked distribution of AUD 3.3608 per security on its perpetual preference shares, subject to board approval by late August. The payment reflects a total annualised rate of 6.7%, linked to the 180-day BBSW plus a margin.

4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Fredon, NRW Holdings’ electrical and mechanical arm, has landed contracts worth around $160 million spanning major infrastructure, health, and electric vehicle projects across Australia, with work scheduled through to mid-2028.

Eden Innovations has unveiled EdenShield®, a new division focused on commercialising advanced carbon nanotube-enhanced materials and dual-fuel systems for defence and critical infrastructure, aiming to tap into a rapidly expanding global aerospace and defence market.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.